Compare THW & YDES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | THW | YDES |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Finance Companies | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 484.8M | 476.8M |
| IPO Year | 2015 | 2024 |
| Metric | THW | YDES |
|---|---|---|
| Price | $12.12 | $6.03 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 111.9K | ★ 440.3K |
| Earning Date | 01-01-0001 | 08-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.18 | $1.70 |
| 52 Week High | $14.50 | $22.00 |
| Indicator | THW | YDES |
|---|---|---|
| Relative Strength Index (RSI) | 34.69 | 54.88 |
| Support Level | $12.04 | $2.33 |
| Resistance Level | $12.87 | $8.89 |
| Average True Range (ATR) | 0.31 | 1.06 |
| MACD | -0.02 | -0.10 |
| Stochastic Oscillator | 18.97 | 32.66 |
Tekla World Healthcare Fund is a diversified closed-end management investment company. Its investment objective is to seek current income and long-term capital appreciation. The Fund mainly invests in equity and debt securities of public and private U.S. and non-U.S. companies that the Fund's investment adviser believes have the potential for above-average growth. The company's investment portfolio includes holdings across various sub-sectors such as pharmaceuticals and biotechnology, healthcare providers and services, real estate investment trusts, medical devices and diagnostics, and other related areas.
YD Bio Ltd is a biotechnology company focused on regulated diagnostics, life science clinical services and healthcare product commercialization. Its operations include DNA methylation-based oncology testing programs in the United States under an LDT framework with CLIA-certified and CAP-accredited laboratory partners. The Company also provides life science distribution and clinical trial supply chain services, including procurement, logistics coordination and compliance-focused support for clinical development programs. It maintains ocular health product commercialization operations in the United States and consumer healthcare distribution activities in Asia. The Company operates in the United States and Taiwan, with Taiwan generating maximum revenue.